Moxifloxacin

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Avelox (Bayer); Moxeza (Alcon)
  • INDICATIONS: Various infections caused by susceptible organisms
  • CLASS: Antibiotic, fluoroquinolone
  • HALF-LIFE: 12 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfuzosin, Aminophylline, Amiodarone, Amitriptyline, Antacids, Arsenic, Artemether/Lumefantrine, Asenapine, Atomoxetine, BCG Vaccine, Benperidol, Bepridil, Bretylium, Chloroquine, Ciprofloxacin, Corticosteroids, Cyclosporine, Degarelix, Didanosine, Disopyramide, Dronedarone, Droperidol, Erythromycin, Gadobutrol, Haloperidol, Hydroxychloroquine, Insulin, Lanthanum, Levomepromazine, Magnesium salts, Mefloquine, Mizolastine, Mycophenolate, Nilotinib, NSAIDs, Oral iron, Oral typhoid vaccine, Pentamidine, Phenothiazines, Pimavanserin, Pimozide, Probenecid, Procainamide, QT prolonging agents, Quinapril, Quinidine, Quinine, Ribociclib, Sevelamer, Sotalol, Strontium Ranelate, Sucralfate, Sulfonylureas, Tetrabenazine, Thioridazine, Tricyclic antidepressants, Vandetanib, Vitamin K antagonists, Warfarin, Zinc, Ziprasidone, Zolmitriptan, Zuclopenthixol

PREGNANCY CATEGORY: C

Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.

Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis.

Moxeza is for topical ophthalmic use only.

SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS

See full prescribing information for complete boxed warning.

Our database has 77 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OCULAR
OTIC
RESPIRATORY
OTHER


Page last updated 03/23/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric